Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

NCT07297563 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia
Treatment

Interventions

DRUG: Rituximab
DRUG: Daratumumab

Sponsor

Institute of Hematology & Blood Diseases Hospital, China